Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge
By
Jamila Raja
Shuo Li
Asal Patterson
Steve R. Martinez
Perry A. Soriano
Xiaowen Wang
Peter Y. Z. Jiang
July 16, 2026
Clinical Scorecard: Case Study: Sustained Remission in Advanced Melanoma After Strategic Rotation and Rechallenge of Immune Checkpoint Inhibitors
At a Glance
Category Detail
Condition Advanced Melanoma Key Mechanisms CTLA-4 blockade and PD-1 blockade Target Population Patients with advanced melanoma and severe immune-related adverse events Care Setting Oncology
Key Highlights
Patient achieved complete remission after ICI rechallenge. Severe irAEs occurred during initial Nivolumab therapy. Strategic rotation to Ipilimumab followed by Nivolumab rechallenge was utilized. Patient remained disease-free for nearly five years post-treatment. No recurrence of prior irAEs after rechallenge. Guideline-Based Recommendations
Diagnosis
Diagnosis of advanced melanoma confirmed through imaging and biopsy. Management
Consider rotation of ICI agents after severe irAEs. Monitoring & Follow-up
Regular surveillance imaging for disease progression. Risks
Severe immune-related adverse events may necessitate treatment discontinuation. Patient & Prescribing Data
59-year-old male with advanced nodular melanoma.
Rechallenge with Nivolumab after Ipilimumab resulted in complete remission.
Clinical Best Practices
Individualized risk-benefit assessment for ICI rechallenge. Management of irAEs with immunosuppressive therapy. Related Resources & Content
